PATENT CLAIM ANALYSIS

Application Number: 15998702
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "183000"]

Abstract:
Administration of a hypoxia activated prodrug in combination with an antiangiogenic agent is useful for treating cancer.

Claim (Index 2):
The method of  claim 1 , wherein the first administration of the hypoxia activated prod rug occurs only after administration of the antiangiogenic agent has resulted in an increased hypoxic fraction of the cancer.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 96.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14367168', '15480250', '13125303', '14043661', '13998269']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7611881033068957
- 35 USC 102 Novelty (BERT): 0.5150346131297807
- Combined Prediction Score: 0.7365727542891842
- Mean Citation Score: 260.037336
- Max Citation Score: 265.96304
- Similarity Product: 189.3845207047844

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test